Close Menu

NEW YORK (GenomeWeb News) – Beckman Coulter yesterday disclosed further terms of its acquisition of Olympus' diagnostics business and fixed the closing cost of the deal at $780 million.

Last week, Beckman said that it would pay for the $800 million acquisition of Olympus' diagnostics business through a combination of around $300 million in Beckman Coulter stock and $500 million in newly issued debt.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.